News | February 09, 2026
Wanbury reports explosive Q3 profit surge, signals strong growth ahead
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
The approved scheme will deliver around 1 million sq ft of state-of-the-art laboratory and research space across a 12-acre site
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
The company maintained a competitive ARPOB while steadily improving occupancy, driven by higher patient volumes and efficient capacity utilization
This achievement validates global demand and catapults Wanbury into high-growth acceleration
Nine-month revenue grew 17.5% to Rs 76,277 lakh, EBITDA climbed to Rs 15,981 lakh, and net profit reached Rs 8,200 lakh
The Poultry Healthcare Division delivered a strong performance, posting 32% revenue growth in Q3 FY26 and 17% growth over the nine-month period
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
Subscribe To Our Newsletter & Stay Updated
